Clinical Trials Logo
  1. Home
  2. CLL/SLL
  3. NCT05791409

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL — AETHER  

CLL/SLL Clinical Trial

Official title:
A Prospective Randomized Phase I/II Trial of Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Clinical Trial Summary

In this study, efficacy and safety of 2 regimens that combine the CD3-CD20 T cell engager epcoritamab with venetoclax will be tested in relapsed/refractory CLL and SLL patients. The trial starts with phase I part to establish the recommended dose level (RDL) of epcoritamab in the combination with venetoclax for the phase II trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05791409
Study type Interventional
Source Stichting Hemato-Oncologie voor Volwassenen Nederland
Contact Arnon Kater
Phone +31 6-11491753
Email a.p.kater@amsterdamumc.nl
Status Recruiting
Phase Phase 1/Phase 2
Start date April 10, 2024
Completion date November 2032
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05487651 - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies Phase 1
Recruiting NCT05590702 - French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings
Withdrawn NCT04660045 - Early Intervention With Acalabrutinib in Patients With High Risk CLL Phase 2
Recruiting NCT04215809 - Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL Phase 1
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1
Not yet recruiting NCT05975164 - the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
Withdrawn NCT05365100 - A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL Phase 1/Phase 2
Recruiting NCT04775745 - Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Phase 1
Not yet recruiting NCT05918276 - Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL Phase 2
Recruiting NCT05920668 - Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
Recruiting NCT05269940 - A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05491044 - A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib Phase 2
Withdrawn NCT05176691 - HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL Phase 1
Terminated NCT04149821 - Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy Phase 2
Recruiting NCT04523428 - REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) Phase 2
Withdrawn NCT04694560 - A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Recruiting NCT06104566 - Global Trial in APG2575 for Patients With CLL/SLL Phase 3
Recruiting NCT06319456 - A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Phase 3
Active, not recruiting NCT03493217 - A Study to Evaluate ICP-022 in Patients With CLL/ SLL Phase 1/Phase 2